• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Syst . Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell ep

tetano

Editor, Senior Moderator
Cell Syst


. 2022 Dec 23;S2405-4712(22)00470-7.
doi: 10.1016/j.cels.2022.12.002. Online ahead of print.
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8[SUP]+[/SUP] T-cell epitopes


David Gfeller[SUP] 1 [/SUP], Julien Schmidt[SUP] 2 [/SUP], Giancarlo Croce[SUP] 3 [/SUP], Philippe Guillaume[SUP] 2 [/SUP], Sara Bobisse[SUP] 4 [/SUP], Raphael Genolet[SUP] 2 [/SUP], Lise Queiroz[SUP] 2 [/SUP], Julien Cesbron[SUP] 2 [/SUP], Julien Racle[SUP] 3 [/SUP], Alexandre Harari[SUP] 4 [/SUP]



Affiliations

Abstract

The recognition of pathogen or cancer-specific epitopes by CD8[SUP]+[/SUP] T cells is crucial for the clearance of infections and the response to cancer immunotherapy. This process requires epitopes to be presented on class I human leukocyte antigen (HLA-I) molecules and recognized by the T-cell receptor (TCR). Machine learning models capturing these two aspects of immune recognition are key to improve epitope predictions. Here, we assembled a high-quality dataset of naturally presented HLA-I ligands and experimentally verified neo-epitopes. We then integrated these data in a refined computational framework to predict antigen presentation (MixMHCpred2.2) and TCR recognition (PRIME2.0). The depth of our training data and the algorithmic developments resulted in improved predictions of HLA-I ligands and neo-epitopes. Prospectively applying our tools to SARS-CoV-2 proteins revealed several epitopes. TCR sequencing identified a monoclonal response in effector/memory CD8[SUP]+[/SUP] T cells against one of these epitopes and cross-reactivity with the homologous peptides from other coronaviruses.

Keywords: CD8(+) T cell epitopes; HLA-I peptidomics; antigen presentation; computational biology; epitope predictions; immunology; machine learning.
 
Back
Top Bottom